BioSkryb Genomics

Whether evaluating surface targets, resistance mechanisms, or subclonal escape, translational decisions depend on seeing the full biological picture. BioSkryb integrates genomic, transcriptomic, and surface protein data from individual cells to support confident target validation across oncology programs, including but not limited to ADC development. Discover how teams reduce uncertainty during early translational decision-making.

In early discovery and translational research, incomplete biological signal leads to false confidence and costly downstream decisions. BioSkryb delivers integrated single-cell DNA, RNA, and surface protein data from the same cell, providing the biological ground truth required for confident platform and target evaluation. See how leading biopharma teams resolve complexity earlier, before it becomes a risk.

Advanced analytics and AI demand accurate, complete biological input. Fragmented or partial datasets introduce risk at scale. BioSkryb provides integrated, genome-scale single-cell multiomic data designed to serve as a reliable foundation for biomarker discovery, predictive modeling, and AI-ready research initiatives. Learn how biopharma leaders build proprietary datasets they can trust.

A recent large-scale single-cell study demonstrates how BioSkryb technology enables matched whole-genome and transcriptome analysis across thousands of individual cells. The work reveals early, actionable insights into clonal evolution in human tissue, validating BioSkryb’s ability to uncover biological ground truth at scale. Explore the science behind the data.

Detection alone is no longer sufficient for oncology decision-making. BioSkryb enables high-fidelity molecular characterization of circulating tumor cells and measurable residual disease, revealing clonal evolution, antigen specificity, and resistance drivers that often remain hidden. Learn how oncology teams generate the depth of evidence needed to inform translational and clinical strategy.

Whether evaluating surface targets, resistance mechanisms, or subclonal escape, translational decisions depend on seeing the full biological picture. BioSkryb integrates genomic, transcriptomic, and surface protein data from individual cells to support confident target validation across oncology programs, including but not limited to ADC development. Discover how teams reduce uncertainty during early translational decision-making.